December 2022 to March 2023
Authors: Serena Fasano and Jean-Guillaume Letarouilly
Di Martino et al (doi: 10.1016/j.semarthrit.2023.152201) aimed to investigate the effect of perioperative exposure to TNF inhibitors (TNFi) on the long-term survival of total hip arthroplasty (THA) in patients with inflammatory arthritis- including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)- from a large regional register of arthroplasty procedures between 2008 and 2019. At an average follow-up of 5 years, survival rates (using any revision surgery as an endpoint) were not significantly different when perioperative TNFi users and non-bDMARD/tsDMARDpatients were compared (p = 0.713), and between TNFi-treated and OA controls (p = 0.123). At the latest available follow-up, 2.5% patients in the TNFi cohort, 3% in the non-bDMARD/tsDMARD cohort, and 0.8% in the OA cohort underwent revision surgery. No significant differences were found comparing the risk of postoperative infection or aseptic loosening among groups.
McEwan T et al (doi: 10.1016/j.semarthrit.2022.152150) performed a systematic literature review on colchicine induced neuromyopathies. A total of 143 cases of neuromyopathy were identified as having a “definite” or “probable” association with colchicine usage. Most of these cases presented with features of both neuropathy and myopathy (n=72, 51%). Cessation of colchicine generally led to complete resolution of symptoms in 70% of cases within a median of 21 days. Colchicine was restarted at reduced doses in 15 cases and 73% had no symptom recurrence.
Lanumolu et al (doi: 10.1016/j.semarthrit.2022.152154) aimed to o describe the incidence of pneumocystis jiroveci pneumonia (PJP) among patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR) using US-based TriNetX electronic health records database. During 547 patient-years of follow-up time, no cases of PJP were identified among 1,168 cases of GCA (incident rate 0 per 1,000 person-years); during 7,446 patient-years of follow up time, one case of PJP was identified out of 15,575 cases of PMR (incident rate 0.07 cases per 1,000 patient-years).
Riedstra NS et al (doi: 10.1016/j.semarthrit.2023.152194) aimed to assess the relationship between acetabular dysplasia (AD) and the risk of incident and end-stage radiographic hip osteoarthritis (RHOA) over 2,5,8 and 10 years. They included 1,002 individuals aged between 45 and 65 from the prospective Cohort Hip and Cohort Knee (CHECK). AD was associated with the development of incident RHOA at 2 years follow-up (OR 2.46, 95% CI 1.00-6.04), 5 years follow-up (OR 2.28, 95% CI 1.20-4.31), and 8 years follow-up (OR 1.86, 95%CI 1.22-2.83). AD was only associated with end-stage RHOA at 5 years follow-up (OR 3.75, 95% CI 1.02-13.77). No statistically significant associations were observed between AD and RHOA at 10-years follow-up.
Serena Fasano
Serena is a consultant rheumatologist at Hospital San Giovanni Bosco in Naples, Italy. Her research interests include Connective tissue diseases, especially Systemic Lupus Erythematosus and Systemic Sclerosis. Serena is a member of the Social Media Sub-Committee.
Jean-Guillaume Letarouilly
Jean-Guillaume is a fellow in rheumatology at Lille University Hospital in Lille, France. His main research focus on spondyloarthritis and its crosstalk with inflammatory bowel diseases and psoriasis. Jean-Guillaume is a member of the Social Media Sub-Committee.